The global stem cell therapy market has exploded — hundreds of clinics now operate across dozens of countries, promising everything from joint repair to cognitive rejuvenation. But regulation is fragmented, quality varies enormously, and the consequences of choosing the wrong clinic can be severe. This guide provides a structured framework for evaluating any stem cell clinic, based on published safety standards, clinical best practices, and the evidence base that distinguishes responsible providers from the rest. [1]

Why clinic choice is a safety decision. Stem cell therapy is not a standardized product — it is a medical procedure whose safety depends entirely on how the cells are sourced, processed, stored, and administered. Unregulated clinics have been associated with serious adverse events including infections, immune reactions, tumor formation, and even death. [2] [3] The International Society for Cell & Gene Therapy (ISCT) and regulatory bodies including the FDA and EMA have published consensus guidelines for cell manufacturing and clinical application — and these guidelines provide the benchmark against which any clinic should be measured.

The difference between a clinic and a factory. Responsible stem cell clinics operate like medical institutions, with physician-led protocols, documented quality systems, and transparent reporting. Unregulated operators often function more like production lines — high patient volume, minimal pre-treatment workup, standardized doses regardless of individual patient factors, and aggressive marketing that promises results the evidence does not support. Understanding this distinction is the first step in protecting yourself.

This guide covers what matters. We walk through each dimension of clinic evaluation: laboratory standards and accreditations, physician credentials and clinical governance, consultation quality and shared decision-making, transparency around cell sourcing and dosing, safety track records and adverse-event reporting, red flags that should make you walk away, and the specific questions you should ask before committing to treatment — whether at VELAR or anywhere else.

The Laboratory: Your First Line of Defense

The quality of a stem cell product is determined long before it reaches the patient — in the laboratory where cells are cultured, characterized, and prepared. A clinic may have a beautiful facility, but if the lab operates without recognized quality standards, the cells you receive are an unknown quantity. [4]

GMP certification is the gold standard. Good Manufacturing Practice (GMP) certification means the laboratory follows internationally recognized quality-control protocols for every step of cell production: environmental monitoring, sterility testing, batch traceability, operator training, and documentation. GMP-grade MSCs are produced under the same quality framework as pharmaceutical products. Clinics that source cells from GMP-certified facilities — or operate their own GMP-compliant cleanrooms — provide a level of quality assurance that non-certified labs cannot match. [5]

ISCT identity criteria matter. The ISCT has published minimal criteria for defining mesenchymal stromal cells: adherence to plastic under standard culture conditions, expression of specific surface markers (CD73, CD90, CD105) and lack of expression of hematopoietic markers (CD45, CD34, CD14 or CD11b, CD79α or CD19, HLA-DR), and trilineage differentiation capacity (osteoblasts, chondroblasts, adipocytes). [6] A clinic should be able to provide a Certificate of Analysis confirming these identity markers for each batch. If they cannot name the markers or provide documentation, their "MSCs" may not be MSCs at all.

Viability and sterility are non-negotiable. Post-thaw viability — the percentage of cells that survive the freezing and thawing process — should exceed 85 percent in a quality product and should be reported transparently. Sterility testing for bacterial, fungal, and mycoplasma contamination must be performed on every batch prior to release. A clinic that cannot produce a recent Certificate of Analysis with viability and sterility data is asking you to accept unknown risk. [7]

Laboratory Checklist

Before treatment, ask for: (1) GMP certification or evidence of GMP-compliant sourcing, (2) Certificate of Analysis with ISCT marker expression, (3) post-thaw viability percentage, (4) sterility testing results for the specific batch you will receive. A responsible clinic provides these documents without hesitation.

Physician Credentials and Clinical Governance

A stem cell clinic is only as good as the clinicians directing your care. The physician who evaluates you, designs your protocol, and oversees your treatment should be qualified to do so — and the relationship should feel like medicine, not sales. [8]

Specialty training matters. Stem cell therapy is not a single discipline — it spans orthopedics, neurology, immunology, aesthetic medicine, and more. Your treating physician should have board certification or equivalent specialist training in the area relevant to your condition. A general practitioner with a weekend course in "regenerative medicine" is not equivalent to an orthopedic surgeon treating musculoskeletal conditions or a neurologist managing neurodegenerative disease.

Ask about experience, not marketing. How many patients with your specific condition has the physician treated? What is their complication rate? Do they publish or present clinical data? A physician who can discuss their case volume, outcomes, and learning curve honestly — including cases that did not respond — demonstrates the clinical maturity you want. A physician who only talks about success stories and cannot quantify their experience should raise concern.

The consultation should feel medical. A thorough pre-treatment consultation includes: a detailed medical history, review of current medications, discussion of previous treatments and their outcomes, physical examination where relevant, laboratory or imaging studies as indicated, and a candid discussion of what MSC therapy can and cannot achieve for your condition. If the consultation feels like a sales pitch — high-pressure closing, limited medical questioning, promises of dramatic results — consider it a red flag. [9]

Cell Sourcing and Transparency

Not all MSCs are created equal. Where the cells come from, how they are processed, and whether they are autologous (your own) or allogeneic (from a donor) all matter — and a responsible clinic is transparent about every link in the chain. [10]

Allogeneic vs. autologous: understand the trade-offs. Autologous cells (typically from bone marrow or adipose tissue) eliminate immunological rejection risk but carry the disadvantages of invasive harvesting, variable cell quality depending on the patient's age and health, and the practical delay between harvesting and treatment. Allogeneic cells (typically from perinatal sources such as Wharton's Jelly) provide consistent quality, immediate availability, and a more potent immunomodulatory profile — but require rigorous donor screening and pathogen testing. [11] Neither option is universally better; the clinic should explain why they recommend one approach over the other for your specific situation.

Know the tissue source. MSCs have been isolated from bone marrow, adipose tissue, umbilical cord, Wharton's Jelly, placental tissue, dental pulp, and other sources. Each source has different biological characteristics — proliferation capacity, secretory profile, differentiation potential — that may influence therapeutic effect. Perinatal sources generally have higher proliferative capacity and lower immunogenicity than adult tissue sources, which is why many advanced clinics favor them. [12] The clinic should name the specific tissue source and explain their rationale for selecting it.

Traceability from donor to dose. Every batch of cells should be traceable from the original donor through every processing step to the final treatment dose. This includes donor consent documentation, infectious disease screening results (HIV, hepatitis B/C, syphilis, HTLV, CMV), processing records, and release testing data. A clinic that cannot provide traceability documentation — or dismisses the request — is not operating to an acceptable safety standard.

Red Flags: When to Walk Away

Some warning signs are universal. Regardless of the clinic's location, marketing claims, or price point, the following red flags should cause you to pause — or withdraw — before committing to treatment.

Ten Red Flags

  1. Guaranteed results. No ethical clinic guarantees outcomes. Stem cell therapy is still investigational for most indications; responsible providers discuss probabilities, not promises.
  2. Treats everything with one protocol. A clinic that uses the same cells, same dose, and same delivery route for every condition — from arthritis to autism to ALS — is not practicing individualized medicine. [13]
  3. No pre-treatment medical evaluation. Skipping a thorough history, physical examination, and relevant diagnostics before administering cells is dangerous. Contraindications must be excluded.
  4. Cannot show laboratory documentation. If the clinic cannot produce a Certificate of Analysis, GMP certification, or sterility/viability data, the cells are an unknown product.
  5. Cash-only, no medical records. Reputable clinics generate medical records, provide informed consent documents, and operate within standard healthcare payment frameworks.
  6. Claims to treat conditions with no published evidence. If there are zero published studies on MSC therapy for the condition the clinic claims to treat, and they present no rationale beyond "stem cells heal everything," skepticism is warranted.
  7. No physician involvement. If your protocol is designed by a sales representative rather than a qualified physician, you are not receiving medical care.
  8. Exaggerated cell counts. Claims of administering "billions of cells" or numbers far outside the published evidence range may indicate either exaggeration or unsafe dosing. [14]
  9. High-pressure sales tactics. Limited-time offers, discounts for immediate commitment, or pressure to decide before you have had time to research independently are hallmarks of a commercial, not clinical, operation.
  10. No follow-up or adverse-event reporting. A responsible clinic tracks patient outcomes after treatment and has a system for reporting and managing adverse events. If there is no follow-up protocol, the clinic is not accountable for results — good or bad.

Questions to Ask Before Committing

Bring these questions to any consultation. A clinic that answers them directly and transparently — with documentation where appropriate — has earned a measure of trust. A clinic that deflects, dismisses, or cannot answer is showing you something important about how they operate.

The most revealing question a patient can ask is: "May I speak with a former patient who had a similar condition?" A clinic that facilitates this — with appropriate consent and privacy protections — is confident in its work. A clinic that always has a reason why this is not possible is hiding something.

— VELAR Clinical Team

Medical Tourism: Special Considerations

Traveling internationally for stem cell therapy adds complexity. The destination country's regulatory framework, the logistics of post-treatment follow-up, and the challenges of recourse if something goes wrong must all be factored into your decision. [15]

Regulation varies dramatically by country. Countries including Japan, South Korea, and the European Union member states have established regulatory pathways for cell therapy products. Others operate with minimal oversight — clinics can open, market, and treat with limited regulatory scrutiny. Thailand, where VELAR is based, has a structured regulatory environment for medical facilities and has attracted a concentration of high-quality international-standard clinics. Understanding where your destination country sits on the regulatory spectrum is essential research.

Plan for follow-up before you travel. The treatment itself is one day — but follow-up can last months or years. Discuss with the clinic what objective measures (imaging, biomarkers, functional assessments) they will use to track your progress, and establish a plan with your home physician for ongoing monitoring before you leave. A responsible clinic provides a structured post-treatment protocol that your local doctor can implement.

Limitations and Realistic Expectations

This guide aims to help patients make informed decisions, but it has important limitations. No checklist can guarantee a positive outcome, and even the most reputable clinics cannot predict individual patient responses to MSC therapy. Stem cell therapy for most indications remains investigational — the evidence base continues to grow, but many applications lack large-scale randomized controlled trials. [16]

Furthermore, clinic selection is only one factor in treatment success. The underlying condition, its duration and severity, the patient's overall health and age, and the inherent biological variability in MSC products all influence outcomes in ways that are partially beyond any clinic's control. The goal of this framework is to help patients eliminate the unsafe and the unaccountable — to ensure that if treatment is pursued, it is pursued in an environment where quality and safety are taken seriously.

At VELAR Center, we invite every prospective patient to tour our facility, review our laboratory documentation, meet our clinical team, and ask every question this guide recommends — before making any commitment. We believe that transparency is not a marketing advantage. It is the minimum standard of care.

References

  1. Sipp D, Caulfield T, Kaye J, et al. Marketing of unproven stem cell-based interventions: a call to action. Science Translational Medicine. 2017;9(397):eaag0426. doi:10.1126/scitranslmed.aag0426 ↩
  2. Bauer G, Elsallab M, Abou-El-Enein M. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Translational Medicine. 2018;7(9):676-685. doi:10.1002/sctm.17-0282 ↩
  3. Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal injection of autologous "stem cells" for AMD. New England Journal of Medicine. 2017;376(11):1047-1053. doi:10.1056/NEJMoa1609583 ↩
  4. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  5. Torre ML, Lucarelli E, Guidi S, et al. Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application. Stem Cells and Development. 2015;24(6):677-685. doi:10.1089/scd.2014.0299 ↩
  6. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  7. Moll G, Ankrum JA, Olson SD, Nolta JA. Improved MSC minimal criteria to maximize patient safety. Stem Cells Translational Medicine. 2022;11(3):246-258. doi:10.1093/stcltm/szab018 ↩
  8. Connolly R, O'Brien T, Flaherty G. Stem cell tourism — a web-based analysis of clinical services available to international travellers. Travel Medicine and Infectious Disease. 2014;12(6):695-701. doi:10.1016/j.tmaid.2014.09.008 ↩
  9. Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell. 2016;19(2):154-157. doi:10.1016/j.stem.2016.06.007 ↩
  10. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nature Biotechnology. 2014;32(3):252-260. doi:10.1038/nbt.2816 ↩
  11. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  12. El Omar R, Beroud J, Stoltz JF, Menu P, Velot E, Decot V. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? Tissue Engineering Part B: Reviews. 2014;20(5):523-544. doi:10.1089/ten.TEB.2013.0664 ↩
  13. Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004–2018: Is efficacy optimal in a narrow dose range? Stem Cells Translational Medicine. 2020;9(1):17-27. doi:10.1002/sctm.19-0202 ↩
  14. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  15. Cohen CB, Cohen PJ. International stem cell tourism and the need for effective regulation. Kennedy Institute of Ethics Journal. 2010;20(1):27-49. doi:10.1353/ken.0.0305 ↩
  16. Squassina A, Meloni A, Chillotti C, Pisanu C. Stem cell therapies in clinical trials: a review of safety and efficacy. Journal of Clinical Medicine. 2023;12(4):1348. doi:10.3390/jcm12041348 ↩